` ALLK (Allakos Inc) vs S&P 500 Comparison - Alpha Spread

ALLK
vs
S&P 500

Over the past 12 months, ALLK has underperformed S&P 500, delivering a return of -70% compared to the S&P 500's 9% growth.

Stocks Performance
ALLK vs S&P 500

Loading
ALLK
S&P 500
Add Stock

Performance Gap
ALLK vs S&P 500

Performance Gap Between ALLK and GSPC
HIDDEN
Show

Performance By Year
ALLK vs S&P 500

Loading
ALLK
S&P 500
Add Stock

Competitors Performance
Allakos Inc vs Peers

S&P 500
ALLK
ABBV
AMGN
GILD
VRTX
Add Stock

Allakos Inc
Glance View

Market Cap
29.5m USD
Industry
Biotechnology

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Redwood City, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

ALLK Intrinsic Value
HIDDEN
Show
Back to Top